

Supplementary Material

Association Between Myasthenia Gravis-Activities of Daily Living (MG-ADL) and EQ-5D-5L Utility Values: The Additional Effect of Efgartigimod on Utilities

Authors:

Sarah Dewilde PhD¹, Cynthia Qi^{2*}, Glenn Phillips PhD², Sergio Iannazzo PhD³, Mathieu F. Janssen PhD⁴

Affiliations

¹ Services in Health Economics SHE, Brussels, Belgium

² argenx US Inc., Boston, Massachusetts, e-mail: cqi@argenx.com

³ argenx Geneva, Switzerland

⁴ Erasmus MC Rotterdam, The Netherlands


*Corresponding author

ORCID OF THE AUTHORS IF AVAILABLE


S Dewilde: 0000-0002-7315-3230

Mathieu Janssen: 0000-0001-6602-6949


Supplementary Figure 1. EQ-5D-5L Mobility Dimension Responses at Baseline and Follow-Up by Treatment




Supplementary Figure 2. EQ-5D-5L Self-Care Dimension Responses at Baseline and Follow-Up by Treatment




Supplementary Figure 3. EQ-5D-5L Usual Activities Dimension Responses at Baseline and Follow-Up by Treatment




Supplementary Figure 4. EQ-5D-5L Pain/Discomfort Dimension Responses at Baseline and Follow-Up by Treatment




Supplementary Figure 5. EQ-5D-5L Anxiety/Depression Dimension Responses at Baseline and Follow-Up by Treatment




Supplementary Figure 6. MG-ADL Talking Item Responses at Baseline and Follow-Up by Treatment




Supplementary Figure 7. MG-ADL Chewing Item Responses at Baseline and Follow-Up by Treatment




Supplementary Figure 8. MG-ADL Swallowing Item Responses at Baseline and Follow-Up by Treatment




Supplementary Figure 9. MG-ADL Breathing Item Responses at Baseline and Follow-Up by Treatment



Supplementary Figure 10. MG-ADL Impairment of Ability to Brush Teeth or Comb Hair Item Responses at Baseline and Follow-Up by Treatment



Supplementary Figure 11. MG-ADL Impairment of Ability to Rise from a Chair Domain Item at Baseline and Follow-Up by Treatment



Supplementary Figure 12. MG-ADL Double Vision Item Responses at Baseline and Follow-Up by Treatment



Supplementary Figure 13. MG-ADL Eyelid Droop Item Responses at Baseline and Follow-Up by Treatment

